SUDA Pharmaceuticals Ltd's (ASX:SUD) (FRA:E4N) Michael Baker introduces Anastsios Karadimitris after signing an exclusive licence agreement with Imperial College London for a novel invariant Natural Killer T (iNKT) cell therapy platform.
As a blood cancer specialist, Karadimitris says how the iNKT cell therapy platform works and can be used in conjunction with chimeric antigen receptors (CARs).
The CAR-iNKT cells are expected to be suitable for off-the-shelf dosing - as one healthy donor can supply cells to treat many patients.
Baker explains how the proceeds of the recent heavily oversubscribed placement that raised $3.65 million is going to be invested.
https://tinyurl.com/8fdtpfk
SUDA Pharmaceuticals Ltd's (ASX:SUD) (FRA:E4N) Michael Baker...
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.010(8.33%) |
Mkt cap ! $136.5M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 13.0¢ | 12.0¢ | $133.5K | 1.063M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 11996 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 367267 | 9 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
12.8¢ |
Change
0.010 ( 6.25 %) |
||||
| Open | High | Low | Volume | ||
| 12.5¢ | 13.0¢ | 12.5¢ | 582454 | ||
| Last updated 14.53pm 03/05/2024 ? | |||||
| ALA (ASX) Chart |